Skip to main content
Livermore
Livermore
ZHEN

Faeth Therapeutics, Inc.

FTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001829802

In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.

Holders of 5% or more of FTH

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Faeth Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of FTH
HolderLatest formStakeChangeFirst filedLatest filingFiling
Khosla Ventures VI, L.P.13G10.20%2.63M sharesNewAug 14, 20261 filingAug 14, 2026SEC
S2G Investments, LLC13G9.99%2.58M sharesNewJun 23, 20261 filingJun 23, 2026SEC
Suvretta Capital Management, LLC13G7.80%2.02M sharesNewJun 23, 20261 filingJun 23, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

27 Schedule 13D and 13G filings on Faeth Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on FTH
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20264:22 PM ETCaligan Partners LPand 1 other13G/A2.40%629.5K shares−7.00 ppfrom 9.40%Below 5%Jun 30, 2026SEC
Aug 14, 20264:15 PM ETTrails Edge Capital Partners, LPand 2 others13G/A2.00%515.3K shares−7.90 ppfrom 9.90%Below 5%Jun 30, 2026SEC
Aug 14, 20264:15 PM ETKhosla Ventures VI, L.P.and 5 others13G10.20%2.63M sharesNewJun 15, 2026SEC
Aug 14, 202612:00 PM ETStemPoint Capital LPand 2 others13G/A0.00%0 shares−9.90 ppfrom 9.90%Below 5%Jun 30, 2026SEC
Jun 23, 20264:35 PM ETSuvretta Capital Management, LLCand 2 others13G7.80%2.02M sharesNewJun 15, 2026SEC
Jun 23, 20264:01 PM ETS2G Investments, LLC13G9.99%2.58M sharesNewJun 15, 2026SEC
Jun 3, 20264:52 PM ETMillennium Management LLCand 3 others13G/A3.10%41.6K shares−6.50 ppfrom 9.60%Below 5%Jun 1, 2026SEC
May 15, 20264:04 PM ETMillennium Management LLCand 3 others13G9.60%128.8K sharesNewFeb 24, 2026SEC
May 15, 202610:00 AM ETStemPoint Capital LPand 2 others13G9.90%132.9K sharesNewMar 31, 2026SEC
May 15, 20268:32 AM ETCaligan Partners LPand 1 other13G9.40%126.0K sharesNewMar 31, 2026SEC
Feb 25, 20264:15 PM ETTrails Edge Capital Partners, LPand 2 others13G9.90%126.0K sharesNewFeb 18, 2026SEC
Mar 7, 2024Newtyn Management, LLC13D/AOld format–––SEC
Feb 13, 2024Newtyn Management, LLC13D/AOld format–––SEC
Nov 3, 2023Newtyn Management, LLC13DOld format–New–SEC
Aug 4, 2023Cambrian BioPharma Inc13G/AOld format–––SEC
Jun 2, 2023Apeiron Investment Group Ltd.13D/AOld format–––SEC
May 23, 2023Apeiron Investment Group Ltd.13D/AOld format–––SEC
Mar 9, 2023Apeiron Investment Group Ltd.13D/AOld format–––SEC
Feb 14, 2023Cambrian BioPharma Inc13G/AOld format–––SEC
Nov 21, 2022Apeiron Investment Group Ltd.13D/AOld format–––SEC
Nov 2, 2022Apeiron Investment Group Ltd.13D/AOld format–––SEC
Jul 19, 2022Apeiron Investment Group Ltd.13DOld format–––SEC
Jun 10, 2022Cambrian BioPharma Inc13G/AOld format–––SEC
Feb 14, 2022H&S Investments I LP13GOld format–New–SEC
Feb 10, 2022Apeiron Investment Group Ltd.13G/AOld format–––SEC
Feb 18, 2021Apeiron Investment Group Ltd.13GOld format–New–SEC
Feb 16, 2021Peyer James13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Faeth Therapeutics, Inc. shares.

No Form 144 notices for Faeth Therapeutics, Inc. are on file.